Tolerogenic dendritic cell reporting: Has a minimum information model made a difference?

Ayesha Sahar1, Ioana Nicorescu2, Gabrielle Barran2

  • 1School of Computing Science, Newcastle University, Newcastle Upon Tyne, United Kingdom.

Peerj
|June 5, 2023
PubMed

Insights

The Minimum Information about Tolerogenic Antigen-Presenting cells (MITAP) reporting framework has had limited adoption (14%) in the tolerogenic dendritic cells (tolDCs) field. While it slightly improves metadata, wider use is needed for standardized reporting in cell therapy research.

Area of Science:

  • Immunology
  • Cell Therapy
  • Biotechnology

Background:

  • Minimum information models standardize scientific reporting for reproducibility and comparison.
  • Tolerogenic antigen-presenting cells (tolAPCs), including tolerogenic dendritic cells (tolDCs), are crucial for immune tolerance and cell therapies.
  • Existing protocols for generating tolDCs are highly variable, necessitating standardized reporting.

Purpose of the Study:

  • To evaluate the impact and adoption of the Minimum Information about Tolerogenic Antigen-Presenting cells (MITAP) framework.
  • To assess the extent to which MITAP has influenced reporting standards in the tolDC research field.

Main Methods:

  • Literature review of a subset of publications on tolDCs.
  • Analysis of the usage of the MITAP framework in the selected literature.
  • Quantification of metadata availability in papers using MITAP versus those not using it.

Main Results:

  • MITAP was utilized in only 14% of the examined tolDC literature.
  • Papers employing MITAP showed a marginal increase in available metadata compared to non-MITAP papers.
  • The adoption of standardized reporting through MITAP has been limited.

Conclusions:

  • MITAP has achieved partial success in the tolDC field.
  • Significant efforts are required to increase the adoption of MITAP and achieve widespread standardized reporting.
  • Further community engagement and integration are necessary for MITAP's broader impact on cell therapy research.